Gamma Medica said it’s closed a $16 million Series A round from Psilos Group Managers.
The Northridge, Calif.-based company said it plans to use the cash to expand the commercial footprint of its LumaGen molecular breast imaging device and the LumaGuide biopsy model.
"This funding enables Gamma Medica to provide leading-edge technology designed to aid breast radiologists in diagnosing difficult cases, particularly in women with dense breast tissue, and provides the financial capability to drive market expansion of MBI. We value our relationship with Psilos and are committed in the fight against breast cancer through early diagnosis," president & CEO Jim Calandra said in prepared remarks.
Sign up to get our free newsletters delivered straight to your inbox
Last week the company revealed $3 million of the round in a regulatory filing.
Gamma Medica earlier this year filed for Chapter 11 bankruptcy, offloading its molecular breast imaging and preclinical imaging businesses to separate buyers.
Deerfield buys 17% stake in CasMed
Various Deerfield Capital Management entities and founder James Flynn acquired a nearly 17% stake in CAS Medical Systems (NSDQ:CASM), buying up a total of 3.2 million shares worth an aggregate $5.7 million at yesterday’s $1.62 closing share price. CasMed priced a public offering of 5.2 million shares at $1.25 per share yesterday, for a total offering value of $6.5 million.
Read more
Pharos, Water Street get in on RTI Biologics’ buyout of Pioneer Surgical
RTI Biologics (NSDQ:RTIX) said it’s changed its name to RTI Surgical now that its $130 million buyout of Pioneer Surgical Technology is complete. Private equity shop Pharos Capital said it cashed out of Pioneer Surgical after leading a $30.5 million round in 2006 and a Series B round worth $17 million in 2008. Water Street Healthcare Partners, another PE player, said it fronted $50 million to RTI to help fund the deal.
Read more
pSivida prices $11M public offering
pSivida (NSDQ:PSDV) priced a public offering of nearly 3.5 million shares at $3.10 apiece, for gross proceeds of roughly $10.8 million.
Read more
Analysts’ ups and downs
- Abbott (NYSE:ABT): Barclays reiterates "equal weight" rating, raises price target to $37 from $35; Leerink Swan reiterates "market perform" rating, lowers price target to $37 from $40.
- Align Technology (NSDQ:ALGN): Cantor Fitzgerald reiterates "hold" rating, raises price target from $35 to $40; JMP Securities raises price target to $47, boosts estimates, "outperform" rating.
- Baxter (NYSE:BAX): Leerink Swann reiterates "outperform" rating, $80 price target.
- Edwards Lifesciences (NYSE:EW): Northland Capital Partners upgrades from “market perform” to “outperform” rating, $74 price target.
- Hologic (NSDQ:HOLX): Piper Jaffray downgrades from “overweight” to “neutral” rating, lowers price target to $21 from $27.
- ICU Medical (NSDQ:ICUI): Piper Jaffray downgrades to "neutral" from "overweight" rating, raises price target from $70 to $71; Roth Capital downgrades from "buy" to "neutral" rating.
- Insulet (NSDQ:PODD): Northland Capital Partners downgrades from “market perform” to “under perform” rating, $28 price target
- Intuitive Surgical (NSDQ:ISRG): JMP Securities downgrades to "underperform" from "market perform" rating, sets $275 price target; Leerink Swann maintains "market perform" rating, reduces price target to $410 from $560.
- Johnson & Johnson (NYSE:JNJ): Citigroup reiterates "buy" rating, raises price target from $95 to $101; Deutsche Bank downgrades from “buy” to “hold” rating, raises price target to $93 from $92.
- Medtronic (NYSE:MDT): Argus raises price target from $54 to $63, “buy” rating.
- NxStage Medical (NSDQ:NXTM): Leerink Swann maintains "outperform" rating, $18 price target.
- ResMed (NYSE:RMD): Goldman Sachs downgrades from “buy” to “neutral” rating; Macquarie upgrades from “neutral” to “outperform” rating.
- Smiths Group (LON:SMIN): JP Morgan Cazenove downgrades from “overweight” to “neutral” rating, lowers price target to £14.60 ($22.05) from £15 ($22.66).
- St. Jude Medical (NYSE:STJ): Barclays reiterates "overweight" rating, raises price target to $57 from $48; BMO Capital Markets raises price target to $52, "market perform" rating; BMO Capital Markets raises price target to $52, "market perform" rating.
- Stryker (NYSE:SYK): Wunderlich downgrades to "hold" from "buy" rating, $71 price target.
- Synergetics (NSDQ:SURG): Wunderlich upgrades from “hold” to “buy” rating, raises price target to $5.80 from $5.50.
